Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome

Resistant Nonalcoholic Fatty Liver Disease Amelioration With Rosuvastatin and Pioglitazone Combination Therapy in a Patient With Metabolic Syndrome

(2014) Daniel M. Riche et al.   ANNALS OF PHARMACOTHERAPY

Synergistic interaction between genetics and disease on pravastatin disposition

(2014) John D. Clarke et al.   JOURNAL OF HEPATOLOGY

Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning?

(2014) Bülent Baran   WORLD JOURNAL OF GASTROENTEROLOGY

Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets

(2013) Z. M. Younossi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels

(2013) Matti J. Tikkanen et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Fetuin-A is linked to improved glucose tolerance after short-term exercise training in nonalcoholic fatty liver disease

(2013) Steven K. Malin et al.   JOURNAL OF APPLIED PHYSIOLOGY

Differential Impact of Statin on New-Onset Diabetes in Different Age Groups: A Population-Based Case-Control Study in Women from an Asian Country

(2013) Chih-Wei Chen et al.   PLoS One

Simvastatin Ameliorates Liver Fibrosis via Mediating Nitric Oxide Synthase in Rats with Non-Alcoholic Steatohepatitis-Related Liver Fibrosis

(2013) Wei Wang et al.   PLoS One

Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice

(2013) Rodrigo Neto-Ferreira et al.   Diabetology & Metabolic Syndrome

Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study

(2012) Vassilios G. Athyros et al.   Archives of Medical Science

Rosuvastatin reduces platelet recruitment by inhibiting NADPH oxidase activation

(2012) Pasquale Pignatelli et al.   BIOCHEMICAL PHARMACOLOGY

Comment on “Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property”

(2012) Francesco Angelico et al.   DIGESTIVE AND LIVER DISEASE

Nonalcoholic Fatty Liver Disease/Steatohepatitis: Epidemiology, Pathogenesis, Clinical Presentation and Treatment

(2012) Sandra Milic et al.   DIGESTIVE DISEASES

Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study

(2012) Takashi Nakahara et al.   HEPATOLOGY RESEARCH

Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study

(2011) Vassilios G. Athyros et al.   CURRENT MEDICAL RESEARCH AND OPINION

Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?

(2011) Niki Katsiki et al.   Current Vascular Pharmacology

Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study

(2011) Hideyuki Hyogo et al.   HEPATOLOGY RESEARCH

Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study

(2011) P. Anagnostis et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Yes! Statins can be given to liver patients

(2011) Ted Bader   JOURNAL OF HEPATOLOGY

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study

(2010) Alexander Tenenbaum et al.   Cardiovascular Diabetology

Central Role of Fatty Liver in the Pathogenesis of Insulin Resistance in Obese Adolescents

(2010) E. D'Adamo et al.   DIABETES CARE

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH

(2010) Yuki Kimura et al.   JOURNAL OF GASTROENTEROLOGY

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

(2010) Vasilios G Athyros et al.   LANCET

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis

(2009) Austin Nelson et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

(2008) Hideyuki Hyogo et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment

(2008) Tim CMA Schreuder et al.   WORLD JOURNAL OF GASTROENTEROLOGY